Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
about
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoringUse of pharmacokinetic modelling to individualize FFP dosing in factor V deficiency.Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution.Monitoring rFVIII prophylaxis dosing using global haemostasis assays.Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report.Recombinant factor VIII in the management of hemophilia A: current use and future promise.Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia ASecondary prophylaxis with factor IX concentrates: continuous infusion.Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.Pharmacokinetics and prophylactic use of FEIBA in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report.Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Individualized factor IX dosing in two brothers: application of longitudinal pharmacokinetic modelling to optimize therapeutic benefit.Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.Living donor liver transplantation for hemophilia with special reference to the management of perioperative clotting factor replacement.Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
P2860
Q33794432-746D7DF7-B5AD-477E-8F50-4E7968CC5DBAQ34485467-A1970DCD-F5BF-4C16-86FB-978266566CD3Q34779399-8958F023-F244-4E76-BD67-A26358F0791EQ36788113-551610C7-683D-450B-8B9B-6A9A0BB0E0A1Q36945970-30D30F9F-F07A-4119-A8DB-96F8A730C3CCQ37230340-70B8BDAD-CA08-4B3A-9F81-482F057E4C1DQ37303186-82D87AE6-976F-4909-ACC0-0AA0712732B5Q37357215-7DA6AEBD-769F-4476-8C4B-D6800C77C2FAQ38205211-2221D22B-1874-4B16-851C-E5E9C889E01BQ38764214-6E2F7237-3D58-4BB7-955D-D84D6E2B26D6Q38944641-351E793F-5244-4D76-91AA-464AFA5723B1Q39995520-A193E2E8-E7FF-4A90-80B1-299C8C6E4020Q43495694-A77EAEC3-B59C-497F-B227-3E2C058998B2Q43684691-DD2934A3-1823-43AC-8D7C-B57DA2C590BCQ45855101-FE68A5C8-9FE5-4010-AD75-B0242A3EA94AQ45864852-8B643D51-913D-447F-8B8A-3A1E9717324AQ45866709-7429EF13-367A-42D6-BB6B-E5DE6B19CE8DQ45866906-327CF928-7B6D-4445-A54B-9A0F1CCCA915Q45868331-F3A4E434-3140-4FE3-9FCA-CECF6225D011Q45869044-927B766E-51FB-4A8D-845D-69E6C655566FQ45869919-F4DE6C21-1FD2-476F-8594-9380A25C6B53Q45870386-81D8D7BF-B3D7-43F8-96F4-21336ACB6FF4Q45873262-5D144A94-336E-49C3-A63E-1ECEC6E1085DQ45879398-88560786-8090-4B29-98B7-3A6DF77BF32DQ45887347-9ECE9EA0-50D3-41CD-A2F0-614A409C5F11Q48543476-94DBFA4D-AFB9-4DA1-BAFF-BC13B0F024B1
P2860
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@ast
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@en
type
label
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@ast
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@en
prefLabel
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@ast
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@en
P2093
P2860
P1433
P1476
Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
@en
P2093
Korth-Bradley J
Shapiro AD
P2860
P304
P356
10.1111/J.1365-2516.2005.01149.X
P577
2005-11-01T00:00:00Z